Fierce Biotech August 12, 2024
Antibody-drug conjugates (ADCs) have been at the center of many a billion-dollar biobuck licensing deal over the last year, but Bivictrix Therapeutics feels like it’s been missing out.
The preclinical company—which is currently listed on the U.K.’s ailing AIM stock exchange—is keen to get its lead bispecific candidate BVX001 into human trials, but currently has just 1.7 million pounds sterling ($2.2 million) to its name. After mulling its options, the biotech’s leadership has decided the best way to raise fresh funds is to go private.
Bivictrix said it has already had “positive initial interactions” with the FDA about moving BVX001, a CD7xCD33 candidate for acute myeloid leukemia, into the clinic. Now, it requires “significant funds to be able to proceed.”
...Today's Sponsors
Today's Sponsor